top of page
Back to first patient

Case Narrative

Relevant Drug Information

T03 is a newly licensed non-steroidal anti-inflammatory drug. The dose you chose is based on the standard dose recommended by the manufacturer, 75mg twice a day. It is a relatively well absorbed drug with an average bioavailability of about 90%. It is primarily cleared by hepatic metabolism, with no active metabolites. Its plasma elimination half-life is approximately 6-8 hours. Large scale clinical trials suggest that analgesic effects are on average observable at plasma concentrations exceeding 2.5mg/L, while anti-inflammatory effects require peak concentrations of at least 5mg/L. Plasma concentrations greater than 7mg/L may be associated with a higher risk of hepatoxicity.

Show patient data

Mr TCK is a 30 Chinese man who has recently been diagnosed as having an inflammatory arthritis of unknown cause. While waiting to complete his diagnostic work-up, you have prescribed a non-steroidal anti-inflammatory drug, empirically named here T03, to relieve his painful right knee. Apart from his arthritis, he is clinically well and does not have evidence of liver or kidney disease.


Multiple Oral Dose (NSAID)

Switch patient
Change population

Would you like to see all the 20 patients in the population?

To go back to single patient view, please click "​Back to first population" button, then click "Yes" button

How would you like to optimize the dose and frequency?

Dose adjustment


Frequency Adjustment

Apply changes
interactive graphs.PNG

Click here to go to "Interactive Pharmacokinetic Graphs"

bottom of page